Tempus AI Brings Artera’s Prostate Test Into Its Platform, Targeting Treatment Choices for Metastatic Patients

Tempus AI moved quickly this week. On May 21, 2026, the precision medicine company launched the ArteraAI Prostate Test for patients with metastatic hormone-sensitive prostate cancer. The prognostic tool, now clinically available through Tempus, marks the first time an externally developed digital pathology algorithm has been integrated into the company’s ecosystem for routine use.

Clinicians can order the test as an add-on to Tempus’ solid tumor portfolio. It works across all ordering channels. Results pair directly with the firm’s next-generation sequencing data. The combination gives doctors a sharper view of each patient’s disease. Short sentences land hard here. Risk meets genomics. Decisions follow.

The test analyzes a patient’s clinical details alongside histopathology images from biopsy slides. An AI algorithm then calculates a personalized estimate of the likelihood of prostate cancer-specific mortality. Roughly 25,000 men receive a new metastatic prostate cancer diagnosis in the United States each year. Many lack clear signals on how aggressive their therapy should be. This offering aims to fill that gap.

But the story started earlier. In February 2025, Tempus and Artera announced an exclusive collaboration to commercialize the ArteraAI Prostate Test across U.S. cancer centers. Artera had already built a track record with its test for localized prostate cancer. That version delivers both prognostic and predictive information. It helps identify which patients benefit from short-term androgen deprivation therapy. The National Comprehensive Cancer Network guidelines recommend it. Validation came from patient-level data across multiple Phase 3 randomized trials.

Now the metastatic version joins the lineup. Tempus’ platform handles the heavy lifting. Its CLIA-certified and CAP-accredited labs process the slides. Integration feels native. Urologists and oncologists gain a digital pathology solution without leaving the Tempus workflow. And the timing aligns with broader moves at the company. Just days before the launch, on May 14, 2026, Tempus expanded its partnership with Bristol Myers Squibb. The two will apply AI and multimodal real-world data to five clinical programs spanning lung, colon and prostate cancers plus Alzheimer’s disease.

Executives spoke plainly about the significance. “By establishing this new digital pathology workflow with the ArteraAI Prostate Test, we are giving clinicians a differentiated tool to better stratify risk and tailor therapy,” said Laura Elster, chief commercial officer of diagnostics at Tempus, according to Clinical Lab Products. “Helping ensure that patients with advanced prostate cancer receive a personalized, evidence-based treatment plan from the very start of their care journey.”

From Artera’s side, the partnership delivers scale. Amanda Lowe, chief operating officer at Artera, noted the shared objective. “From the start of our Tempus collaboration, our goal has been to deliver Artera’s AI-powered insights to Tempus customers in a streamlined, convenient, and impactful way,” she said in the same report.

The collaboration carries weight for both firms. Tempus connects to more than half of all oncologists in the country. Artera brings algorithms trained on vast multimodal datasets. Their combined approach moves beyond single-modality genomics. Images. Clinical variables. Outcomes from past trials. All feed the model. The result? A number that quantifies mortality risk in a disease where intensity of care decisions carry high stakes.

Wall Street reacted with interest. Shares of Tempus, ticker TEM, have shown volatility typical of AI health companies. A recent analysis on Yahoo Finance highlighted an implied upside of more than 60 percent and noted the stock appeared oversold on technical measures. Revenue growth continues. The company reported higher first-quarter 2026 revenue compared with the prior year, though net losses remained substantial.

This launch also reflects a larger pattern. Pathology slides sit unused in many hospitals. Digital scanners and AI models can extract signals invisible to the human eye. Tempus has invested heavily in its own AI capabilities, including the Lens platform now deployed in the Bristol Myers Squibb work. Bringing in an external algorithm validated externally signals confidence. It also accelerates availability. No need to build everything in-house.

Prostate cancer treatment has grown more nuanced. For metastatic hormone-sensitive cases, options range from standard hormone therapy to intensified regimens that add chemotherapy or novel agents. Overtreatment risks side effects. Undertreatment risks progression. A validated risk score helps thread that needle. The ArteraAI test builds on earlier success in localized disease. There, it not only predicts outcomes but forecasts which men gain from added therapy. Early data suggest similar predictive power may emerge in the metastatic setting, though longer follow-up continues.

Industry watchers point to the speed of adoption. The test became available for clinical use within months of deeper integration talks. Orders flow through existing Tempus channels. Reports return quickly. Such frictionless deployment matters in community oncology settings where most patients receive care. Tempus’ earlier Next Pathways program already reached 13 community health systems for advanced lung cancer. The prostate effort extends that reach.

Yet questions linger. How will payers respond to the added cost? Will community oncologists incorporate the score into routine practice? Real-world evidence will decide. Tempus and Artera plan to generate that evidence. Their joint datasets grow daily. And the expanded Bristol Myers Squibb agreement hints at future applications. Prostate trials sit among the initial targets.

For now, the immediate impact centers on those 25,000 newly diagnosed men each year. Their doctors gain one more data point. Not a crystal ball. A probability. One that arrives alongside genomic alterations, PSA trends and imaging. The composite picture sharpens. Treatment plans adjust accordingly.

Tempus continues to position itself at the intersection of data, AI and clinical delivery. The ArteraAI integration represents a concrete step. External innovation flows into its platform. Clinicians benefit. Patients stand to gain the most. Concrete progress in a complex disease. Nothing more. Nothing less.